To provide a composition and method for treating or preventing hyperacute rejection.
The invention relates to mucin-immunoglobulin fusion polypeptides, methods for producing the same and methods for treating or preventing hyperacute rejection and more particularly the mucin part of the fusion polypeptides has been glycosylated by an alpha 1, 3-galactosyltransferase and a beta 1, 6 N-acetylglucosaminyltransferase. This is based on that carbohydrate epitope Galα1, 3Gal(αGal) may be specifically expressed in high density by different core sugar chains on the main chain of mucin type protein. Such the αGal epitope of high density causes increase of binding or removal (that is, adsorption) of anti-αGal compared with free sugars or brings about an αGal determinant combined with solid phase. Here, the polypeptide is called as αGal fusion polypeptide.
LIU JINING
GUSTAFSSON ANKI
Takaaki Yasumura
Natsuki Morishita